

Ionic Liquids Provide Unique Opportunities for Oral Drug Delivery: Structure Optimization and In Vivo Evidence of Utility

Hywel D. Williams, Yasemin Sahbaz, Leigh Ford, Tri-Hung Nguyen, Peter J. Scammells* and Christopher J. H. Porter*

Contents

Table S1 The composition of self-emulsifying drug delivery systems (SEDDS)	Page 2
Table S2 Pharmacokinetic parameters for danazol after oral administration	Page 3
Histology Data	Page 4
Figure S1 Light microscopy image of the non-glandular stomach of a rat following administration of SEDDS _{lipid}	Page 4
Figure S2 Light microscopy image of the non-glandular stomach of 4 rats that were administered SEDDS _{C₁₈SO₄}	Page 5
Figure S3 Schematic to illustrate the possible mechanisms through which typical lipid and self-emulsifying drug delivery systems present incorporated drug to the absorptive membrane in the small intestine in the presence of digestion enzymes and natural solubilisers bile salts and phospholipids.	Page 6
Chemistry Experimental	Page 7
NMR Spectra	Page 14
HPLC Data	Page 23
References	Page 26

Table S1 The composition of self-emulsifying drug delivery systems (SEDDS) and danazol equilibrium solubility in these SEDDS (37°C. N=3, ± 1 sd).

Name	Composition (% w/w)	Danzol solubility (mg g ⁻¹)
SEDDS _{Lipid}	30% lipid (soybean oil: Maisine TM 35-1, 1:1), 60% Cremophor [®] EL and 10% ethanol.	34.2 ± 0.4
SEDDS _{N_{Tf}2}	30% [hhcpy][NTf ₂], 60% Cremophor [®] EL and 10% ethanol.	34.1 ± 2.4
SEDDS _{N(CN)₂}	30% [hhcpy][N(CN) ₂], 60% Cremophor [®] EL and 10% ethanol.	51.7 ± 0.6
SEDDS _{C₁₀SO₄}	30% [C ₈ m _β py][C ₁₀ SO ₄], 60% Cremophor [®] EL and 10% ethanol.	52.6 ± 0.7
SEDDS _{C₁₈SO₄}	30% [C ₈ m _β py][C ₁₈ SO ₄], 60% Cremophor [®] EL and 10% ethanol.	45.6 ± 2.0

Table S2 Summary of the pharmacokinetic parameters for danazol after oral administration to overnight fasted rats in either lipid or ionic liquid containing SEDDS or a crystalline suspension formulation. Data is normalised to a 25 mg.kg⁻¹ dose. Values are expressed as means (n≥4) ± SEM.

	AUC _{0-8h} (ng h ml ⁻¹)	C _{max} (ng ml ⁻¹)	T _{max} (h)	Relative bioavailability (%) ^[a]
SEDDS _{Lipid}	498.3 ± 149.8	243.8 ± 88.5	1.3 ± 0.2	100
SEDDS _{NTf₂}	96.0 ± 11.4	39.6 ± 9.6	3.3 ± 1.6	19.3
SEDDSC ₁₀ SO ₄	154.8 ± 17.9	36.1 ± 3.7	6.5 ± 0.4	31.1
SEDDSC ₁₈ SO ₄	485.4 ± 34.9	115.4 ± 10.7	4.6 ± 0.3	97.4
Crystalline suspension	112.3 ± 20.5	37.9 ± 10.4	0.8 ± 0.3	22.5

^[a] Relative bioavailability (%) of the ionic liquid containing SEDDS and the crystalline formulations in comparison to the corresponding SEDDS_{Lipid}, expressed as the ratio of the dosage-normalized AUC_{0-8h}. AUC; area under the plasma concentration-time curve. C_{max}; maximum plasma concentration. T_{max}: time to reach C_{max}.

Histology of gastric and intestinal regions of the rat

Method: At the conclusion of the pharmacokinetic study and after the collection of the last blood sample (24 h), each animal was euthanised with penobarbitone (550 mg/kg) administered via the carotid artery cannula. Immediately after euthanasia the stomach and duodenum were removed, dissected and rinsed with saline prior to being placed in a 5% v/v formaldehyde solution. The stomach from untreated (blank) rats were also taken and processed in the same manner for a control comparison. All samples were sent to Gribbles Veterinary Pathology (Clayton, Australia) where glandular and non-glandular stomach and duodenal sections underwent blinded histological examination, imaging and scoring.

Results: Figure S1 below is a representative light microscopy image (x100 magnification) of the rat non glandular stomach 24 hours after administration SEDDS_{lipid}. The histological assessment concluded that the non-glandular stomach consisted of normal keratinized epithelium (red arrow) and unremarkable lamina propria (Indicated by black arrow). Additional examination of the glandular stomach and the small intestine also did not reveal any evidence of damaged epithelia. The observations of no histological damage were consistent across animals administered SEDDS_{lipid}.




Fig. S1 Light microscopy image of the non-glandular stomach of a rat following administration of SEDDS_{lipid}

For rats administered SEDDS_{C18S04}, there was no evidence of toxicity in either the glandular stomach or the small intestine. Similarly, in the non-glandular stomach (Figure S2), in rats 1 and 3, the histological assessment confirmed normal keratinized epithelium (red arrow) and unremarkable lamina propria (black arrow) 24 hours after administration SEDDS_{C18S04}. In rat 2 and rat 4, in the non-glandular stomach, some evidence of irritancy was apparent. In rat 2 (Figure S2), the red arrow points to some evidence of epithelial necrosis and erosion while the black arrows point to some evidence of cell infiltration into the lamina propria. In rat 4, the red arrow points to some moderate epithelial vacuolation of non-glandular stomach and the black arrow points to some moderate inflammatory cell infiltration into lamina propria.




Fig. S2 Light microscopy image of the non-glandular stomach of 4 rats that were administered SEDDS_{C18S04}




Fig. S3 Schematic to illustrate the possible mechanisms through which typical lipid (A) and IL (B) self-emulsifying drug delivery systems present incorporated drug to the absorptive membrane in the small intestine in the presence of digestion enzymes and natural solubilisers bile salt (BS) and phospholipids (PL). D = drug molecule.

Figure S3 provides a schematic diagram to illustrate the likely mechanism of drug absorption from an IL-based SEDDS formulation in comparison to a lipid based self emulsifying drug delivery system (SEDDS_{lipid}). SEDDS_{lipid} are rapidly digested in the small intestine under the action of pancreatic enzymes, and digestion products are solubilized in bile salt micelles (that are secreted in bile) to form mixed bile salt-lipid digestion product micelles. These small micellar structures readily diffuse across the unstirred water layer present adjacent to the absorptive membrane and promote drug (and lipid) absorption. In this way drug is able to ‘hijack’ the intrinsic lipid absorption pathway to the intestinal wall, where drug and digested lipids are absorbed. In contrast, SEDDS containing ILs are not digested and instead simply mix with intestinal fluids (including bile). ILs forming large colloids in intestinal fluids (e.g., SEDDS_{NTF₂}) are therefore likely to show drug absorption profiles that are limited by inefficient diffusion of drug to the intestinal wall. In contrast, ILs with amphiphilic properties such as the alkyl sulfate ILs interact readily with endogenous bile salt micelles to form highly dispersed colloidal particles with particles sizes that are similar to that of endogenous micellar species. These small particulates allow improved access to the absorptive surface and therefore enhanced bioavailability. The structure of the IL-based micelles, however, appears to vary and to be sufficiently different to that of lipid-BS mixed micelles to, in some cases, allow for considerably more controlled drug release and therefore sustained drug absorption.

Chemistry Experimental


Lithium triflimide (Aldrich, 97%), potassium hexafluorophosphate (Fluka, 98%), sodium octyl sulfate (Sigma, ~95%), methyl iodide (Sigma-Aldrich, 99%), butyl iodide (Fluka \geq 98%), ethyl bromoacetate (Merck, $>$ 98%), toluene (Merck, GR, \leq 0.03% H₂O), acetonitrile (Merck, Chromatography grade, \leq 0.02% H₂O), diethyl ether (Merck, GR, \leq 0.03% H₂O) were procured from the commercial supplier and used without any pre-treatment. The ¹H and ¹³C NMR spectra of the purified products were recorded in CDCl₃ (Cambridge Isotope Laboratories Inc., 99.8% D) or DMSO d₆ (Cambridge Isotope Laboratories Inc., 99.9% D) on a Bruker Avance DPX 300 spectrometer at 400 and 100 MHz, respectively. High resolution mass spectra were obtained using a Waters LCT Premier XE time-of-flight mass spectrometer fitted with an electrospray (ESI) ion source and controlled with MassLynx software version 4.5. Low resolution mass spectra using electrospray ionisation (ES-MS) were obtained using a Micromass PlatformII instrument. Unless otherwise stated, cone voltage was 20 eV. Ionic liquid purity was assessed by RP-HPLC using an Agilent 6100 Series Single Quad LC/MS Agilent 1200 Series HPLC (pump: 1200 Series G1311A quaternary pump, autosampler: 1200 Series G1329A, detector: 1200 Series G1314B variable wavelength detector) fitted with a Luna C8(2) 5u 50X 4.6mm 100A column (column temperature: 30°C, injection volume: 5uL, solvent A: water plus 0.1% formic acid, solvent B: acetonitrile with 0.1% formic acid, gradient: 5-100% B over 10 min). Nicotinate esters were prepared from nicotinoyl chloride HCl salt by treating a suspension of the salt in cold (-10°C) CH₂Cl₂ with triethylamine and the corresponding alcohol as previously reported.¹

3-(Butoxycarbonyl)-1-methylpyridinium bis(trifluoromethylsulfonyl)amide:

See Reference 2.

3-(Hexyloxycarbonyl)-1-methylpyridinium bis(trifluoromethylsulfonyl)amide:

Hexyl nicotinate (466 mg, 2.25 mmol) was dissolved in 2 mL anhydrous toluene, MeI (170 μ L, 2.73 mmol) was added and the resulting solution was stirred protected from light for 1 h. The mixture was then heated at 40 °C for 24 h. The reaction mixture was




cooled to room temperature and diluted with 10 mL distilled water, the organic layer was decanted and the aqueous layer was washed with a further 3 x 5 mL diethyl ether. The aqueous layer was then treated with lithium bis(trifluoromethylsulfonyl)amide (720 mg, 2.5 mmol) in 2 mL distilled water. The resulting solution was stirred at room temperature for 20 min. The reaction mixture was diluted with 10 mL CH₂Cl₂ the separated aqueous layer was washed with a further 3 x 10 mL

CH₂Cl₂ the combined organic layers were washed with 10 mL portions of cold distilled water until negative to a AgNO₃ precipitate test. The organic solution was dried (MgSO₄), filtered, and concentrated in vacuo. The ionic liquid was dried overnight at 65 °C under high vacuum. Yield 98%.

¹H NMR (DMSO-d₆) δ 9.52 (dd, *J* = 1.7, 1.2 Hz, 1H), 9.17 (m, 1H), 8.96 (dddd, *J* = 8.0, 1.7, 1.3, 0.4 Hz, 1H), 8.25 (dd, *J* = 8.0, 6.2 Hz, 1H), 4.43 (s, 3H), 4.40 (t, *J* = 6.6 Hz, 2H), 1.71-1.79 (m, 2H), 1.39-1.45 (m, 2H), 1.31 (dq, *J* = 7.2, 3.6 Hz, 4H), 0.88 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (DMSO-d₆) δ 161.8, 148.9, 146.7, 144.7, 129.5, 127.9, 119.5 (q, *J*_{C-F} = 319.8 Hz), 66.5, 48.3, 39.5, 30.9, 28.0, 25.0, 22.0, 13.9. HRMS +ve calcd 222.1489 found 222.1499, -ve calcd 279.9178 found 279.9172.

1-Methyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:

Octyl nicotinate (465 mg, 2.00 mmol) was dissolved in 2 mL anhydrous toluene, MeI (290 μL, 4.60 mmol) was added and the resulting solution was stirred protected from light for 1 h. The mixture was then heated at 40 °C for 48 h. The reaction




mixture was cooled to room temperature and diluted with 10 mL hot diethyl ether, the heterogenous mixture was sonicated for 10 min and the organic layer was carefully decanted, this was repeated a further 3 times. The resulting residue was dissolved in 5 mL anhydrous MeCN and then treated with lithium bis(trifluoromethylsulfonyl)amide (720 mg, 2.5 mmol). The resulting solution was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo the resulting residue dissolved in 50 mL CH₂Cl₂ the organic solution was washed with 10 mL portions of cold distilled water until negative to a AgNO₃ precipitate test. The organic solution was dried (MgSO₄), filtered, and concentrated in vacuo. The ionic liquid was dried overnight at 65 °C under high vacuum. Yield 96%.

¹H NMR (DMSO-d₆) δ 9.52 (td, *J* = 1.2, 0.6 Hz, 1H), 9.16-9.18 (m, 1H), 8.95-8.97 (m, 1H), 8.23-8.26 (m, 1H), 4.43 (s, 3H), 4.40 (t, *J* = 6.6 Hz, 2H), 1.75 (dt, *J* = 14.5, 7.1 Hz, 2H), 1.37-1.45 (m, 2H), 1.22-1.36 (m, 8H), 0.86 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (DMSO-d₆) δ 161.7, 148.8, 146.7, 144.7, 129.5, 127.9, 119.5 (q, *J*_{C-F} = 320.0 Hz), 66.5, 48.3, 39.5, 31.2, 28.6, 28.6, 28.0, 25.3, 22.1, 13.9. HRMS +ve calcd 250.1802 found 250.1793; -ve calcd 279.9178 found 279.9185.

3-(Butoxycarbonyl)-1-butylpyridinium bis(trifluoromethylsulfonyl)amide:

Butyl nicotinate (620 mg, 3.46 mmol) was dissolved in 5 mL anhydrous toluene, *n*-BuI (430 μL, 3.78 mmol) was added and the resulting solution was stirred protected from light for 1 h. The mixture was then heated at




reflux for 24 h. The reaction mixture was cooled to room temperature and diluted with 10 mL distilled water, the organic layer was decanted and the aqueous layer was washed with a further 3 x 5 mL diethyl ether. The aqueous layer was then treated with lithium bis(trifluoromethylsulfonyl)amide (1.09 g, 3.81 mmol) in 2 mL distilled water. The resulting solution was stirred at room temperature for 20 min. The reaction mixture was diluted with 10 mL CH₂Cl₂ the separated aqueous layer was washed with a further 3 x 10 mL CH₂Cl₂ the combined organic layers were washed with 10 mL portions of cold distilled water until negative to a AgNO₃ precipitate test. The organic solution was dried (MgSO₄), filtered, and concentrated in vacuo. The ionic liquid was dried overnight at 65 °C under high vacuum. Yield 98%.

¹H NMR (DMSO-d₆) δ 9.60 (s, 1H), 9.28 (dt, *J* = 6.1, 1.4 Hz, 1H), 8.98 (dt, *J* = 8.2, 1.4 Hz, 1H), 8.26-8.29 (m, 1H), 4.71 (t, *J* = 7.6 Hz, 2H), 4.41 (t, *J* = 6.5, 2H), 1.91 (dt, *J* = 15.2, 7.6 Hz, 2H), 1.75 (dt, *J* = 14.6, 7.0 Hz, 2H), 1.37-1.50 (m, 2H), 1.32 (dq, *J* = 15.1, 7.5 Hz, 2H), 0.93 (dt, *J* = 9.9, 7.4 Hz, 6H). ¹³C NMR (DMSO-d₆) δ 161.7, 147.8, 145.9, 145.0, 130.2, 128.3, 119.5 (q, *J*_{C-F} = 321.9 Hz), 66.2, 61.0, 32.8, 30.0, 18.8, 18.5, 13.5, 13.3. HRMS +ve calcd 236.1645 found 236.1645; -ve calcd 279.9178 found 279.9181.

See also reference [4].

1-Hexyl-3-(hexyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:

Hexyl nicotinate (315 mg, 1.52 mmol) was dissolved in 2 mL anhydrous toluene, 1-bromohexane (255 μL, 1.82 mmol), NaI (228 mg, 1.52 mmol) was added and the resulting solution was stirred protected from light for 1 h. The mixture was then heated to reflux




for 72 h. The reaction mixture was cooled to room temperature and diluted with 10 mL hot petroleum spirits, the mixture was sonicated and the organic phase was decanted, this was repeated twice. The resulting residue was dissolved in 10 mL anhydrous CH₂Cl₂ and treated with lithium bis(trifluoromethylsulfonyl)amide (483 mg, 1.68 mmol). The resulting mixture was stirred overnight at room temperature. The reaction mixture was filtered, the precipitate washed with portions of anhydrous CH₂Cl₂, the combined organic filtrates were washed with 10 mL portions of cold distilled water until negative to a AgNO₃ precipitate test. The organic solution was dried (MgSO₄), filtered, and concentrated in vacuo. The ionic liquid was dried overnight at 65 °C under high vacuum. Yield 95%.

¹H NMR (DMSO-d₆) δ 9.60 (s, 1H), 9.28 (dt, *J* = 6.1, 1.3 Hz, 1H), 8.98 (dt, *J* = 8.3, 1.5 Hz, 1H), 8.28 (dd, *J* = 8.0, 6.3 Hz, 1H), 4.70 (t, *J* = 7.5 Hz, 2H), 4.40 (t, *J* = 6.6 Hz, 2H), 1.92 (quin, *J* = 7.1 Hz, 2H), 1.76 (dt, *J* = 14.6, 7.1 Hz, 2H), 1.28-1.46 (m, 12H), 0.85-0.90 (m, 6H). ¹³C NMR (DMSO-

δ 161.7, 147.8, 145.9, 145.03, 130.1, 128.4, 119.5 (q, $J_{C-F} = 321.9$ Hz), 66.5, 61.2, 30.9, 30.6, 28.0, 25.2, 25.0, 25.0, 22.0, 13.9, 13.8. HRMS +ve calcd 292.2271 found 292.2280 –ve calcd 279.9178 found 279.9186.

1-Hexyl-3-(hexyloxycarbonyl)pyridinium dicyanamide:


Hexyl nicotinate (315 mg, 1.52 mmol) was dissolved in 2 mL anhydrous toluene, 1-bromohexane (255 μ L, 1.82 mmol), NaI (228 mg, 1.52 mmol) was added and the resulting solution was stirred protected from light for 1h. The mixture was then heated to reflux for 72 h. The reaction mixture was cooled to rt and diluted with 10 mL hot petroleum spirits, the mixture was sonicated and the organic phase was decanted, this was repeated twice. The residue was dissolved in anhydrous MeOH, with an treated with freshly prepared $\text{AgN}(\text{CN})_2$ (1.68 mmol) (AgNO_3 and $\text{NaN}(\text{CN})_2$ in distilled water at 40°C for 1 h, then high vacuum for 2 h with stirring overnight, the resulting suspension was filtered, the filtrate was concentrated *in vacuo* and then taken up in 5 mL anhydrous CH_2Cl_2 and cooled to -20 °C overnight, the resulting suspension was filtered and the organic solution concentrated in vacuo to give the desired IL, which was dried overnight at 65 °C under high vacuum. Yield 92%.



^1H NMR (DMSO-d_6) δ 9.60 (s, 1H), 9.28 (dt, J 6.1, 1.1 Hz, 1H), 8.98 (dt, $J = 8.1, 1.4$ Hz, 1H), 8.28 (dd, $J = 8.1, 6.1$ Hz, 1H), 4.70 (t, $J = 7.6$ Hz, 2H), 4.40 (t, $J = 6.6$ Hz, 2H), 1.92 (quin, $J = 7.1$ Hz, 2H), 1.75 (quin, $J = 7.3$ Hz, 2H), 1.42 (quin, $J = 7.3$ Hz, 2H), 1.31 (dd, $J = 8.5, 4.6$ Hz, 10H), 0.86-0.90 (m, 6H). ^{13}C NMR (DMSO-d_6) δ 161.7, 147.8, 145.9, 145.0, 130.1, 128.4, 119.1, 66.5, 61.2, 30.9, 30.8, 30.6, 28.0, 25.0, 24.9, 22.0, 21.8, 13.9, 13.8. HRMS +ve calcd 292.2271, found 292.2282.

1-Octyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:

To a suspension of nicotinic acid (0.62 g, 5.0 mmol), potassium carbonate (0.76 g, 5.5 mmol) in 5 mL of anhydrous MeCN was added 1-bromooctane (3.65 mL, 21.1 mmol). The resulting solution was stirred at room temperature for 2 h, then heated to gentle reflux for 4 days. The reaction mixture was filtered, washing with CHCl_3 , the organic solution was concentrated in vacuo to give a residue which was shaken with 3 x 30 mL portions of 4 : 1 petroleum spirits : diethyl ether to give a brown solid. The solid was dissolved in 10 mL anhydrous CH_2Cl_2 and treated with lithium bis(trifluoromethylsulfonyl)amide (1.58 g, 5.5 mmol) and stirred overnight at room temperature. The resulting solution was extracted with 3 x 30




mL cold distilled water, the third water portion was negative to a AgNO_3 precipitate test. The organic solution was dried (MgSO_4), filtered and concentrated *in vacuo*, the ionic liquid was dried overnight at 65 °C under high vacuum. Yield 85%.

^1H NMR (400 MHz, DMSO-d_6) δ 9.59 (s, 1H), 9.27 (d, $J = 6.1$ Hz, 1H), 8.97 (d, $J = 8.1$ Hz, 1H), 8.26-8.29 (m, 1H), 4.69 (t, $J = 7.5$ Hz, 2H), 4.39 (t, $J = 6.6$ Hz, 2H), 1.92 (quin, $J = 6.8$ Hz, 2H), 1.72-1.79 (m, 2H), 1.42 (dt, $J = 14.8$ and 7.3 Hz, 2H), 1.21-1.33 (m, 18H), 0.84-0.87 (m, 6H). ^{13}C NMR (100 MHz, DMSO-d_6) δ 161.7, 147.8, 145.9, 145.0, 130.1, 128.4, 119.5 (q, $J_{\text{C-F}} = 321.9$ Hz), 66.4, 61.2, 31.2, 31.1, 30.8, 28.6, 28.6, 28.4, 28.4, 28.0, 25.4, 25.3, 22.1, 22.0, 13.8, 13.8. HRMS +ve calcd 348.2897 found 348.2897, -ve calcd 279.9178 found 279.9185.

1-Methyl-3-octylpyridinium hexyl sulfate:

The precursors, hexylsulfate ammonium salt and 1-octyl-3-methylpyridinium bromide were initially synthesized according to a modified literature procedure.¹ A mixture of 1-hexanol (5.11 g, 50 mmol) and sulfamic acid (4.86 g, 50 mmol) was heated at 110 °C for 24 h in a moisture guarded assembly. The resulting mixture was allowed to cool to room temperature. The solidified product was crushed and stirred in hexane (300 mL) for 1 h. After the filtration of hexane, the compound was washed with hexane (3 x 50 mL) and dried under reduced pressure. The crude product was stirred in CH_2Cl_2 (100 mL) for 1 h and precipitated with hexane (500 mL), filtered and washed with hexane (3 x 50 mL). The salt was finally dried under reduced pressure to give pure target product, hexyl sulfate ammonium salt. Yield 83%.




A mixture of 3-methylpyridine (15.52 g, 166.7 mmol) and 1-bromooctane (38.62 g, 199.9 mmol) in toluene (200 mL) was stirred for 1 h at rt under nitrogen before being heated at 110 °C overnight. The completion of reaction was marked by the separation of ionic liquid. The reaction was cooled to rt and the toluene was decanted. The IL was mixed with fresh toluene (200 mL) and left in the fridge overnight, which resulted in formation of white solid, 1-octyl-3-methylpyridinium bromide. The toluene was decanted and the product was washed with diethyl ether (4 x 200 mL). Yield 97%.

1-Octyl-3-methyl pyridinium bromide (1.43 g, 5.0 mmol) was dissolved in water (20 mL) and a solution of hexylsulfate ammonium salt (1.0 g, 5.0 mmol) in water (20 mL) was added. The solution was stirred at rt for 10 min, before being extracted with CH_2Cl_2 (3 x 20 mL). The combined extracts were washed with distilled water (3 x 20) until a negative AgNO_3 test was obtained. The organic layer was dried (anhydrous MgSO_4), filtered and evaporated to afford the desired product. The ionic liquid was dried overnight at 60 °C under high vacuum. Yield 94%.

^1H NMR (DMSO- d_6) δ 8.99 (s, 1H), 8.91 (d, J = 6.0 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.05 (dd, J = 8.0, 6.0 Hz, 1H), 4.53 (t, J = 7.4 Hz, 2H), 3.67 (t, J = 6.6 Hz, 2H), 2.50 (s, 3H), 1.91 (quin, J = 7.4 Hz, 2H), 1.47 (quin, J = 6.6 Hz, 2H), 1.34-1.17 (br s, 16H), 0.86 (2 x t, 6H). ^{13}C NMR (DMSO- d_6) δ 145.7, 144.4, 142.0, 138.8, 127.3, 65.6, 60.5, 31.2, 31.0, 30.8, 29.1, 28.5, 28.4, 25.5, 25.2, 22.1, 22.0, 17.7, 13.8, 13.7. HRMS +ve calcd 206.1903 found 206.1906 –ve calcd 181.0540 found 181.0537.

1-Methyl-3-octylpyridinium decyl sulfate:


Decylsulfate ammonium salt was synthesised using the same procedure used to prepare hexylsulfate ammonium salt. Yield 77%. 1-Octyl-3-methyl pyridinium bromide (8.61 g, 30.07 mmol) was dissolved in water (100 mL) and a solution of decylsulfate ammonium salt (7.68 g, 30.07 mmol) in water (100 mL) was added. This solution was stirred for 10 min before being extracted with CH_2Cl_2 (3 x 100 mL). The combined extracts were washed with distilled water (3 x 100 mL) until a negative AgNO_3 test was obtained. The organic layer was dried (anhydrous MgSO_4), filtered and evaporated to afford the desired product. The ionic liquid was dried overnight at 60 °C under high vacuum. Yield 97%.



^1H NMR (DMSO- d_6) δ 9.02 (s, 1H), 8.93 (d, J = 6.0 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.05 (dd, J = 8.0, 6.0 Hz, 1H), 4.55 (t, J = 7.4 Hz, 2H), 3.68 (t, J = 6.7 Hz, 2H), 2.50 (s, 3H), 1.91 (quin, J = 7.4 Hz, 2H), 1.47 (quin, J = 6.7 Hz, 2H), 1.33-1.14 (br s, 24H), 0.85 (2 x t, 6H), ^{13}C NMR (DMSO- d_6) δ 145.7, 144.2, 142.0, 138.8, 127.3, 65.4, 60.6, 31.3, 31.1, 30.7, 29.1, 29.0, 29.0, 28.8, 28.7, 28.4, 28.4, 25.5, 25.4, 22.1, 22.0, 17.8, 13.9, 13.9. HRMS +ve calcd 206.1903 found 206.1910 –ve calcd 237.1166 found 237.1163.

1-Methyl-3-octylpyridinium octadecyl sulfate:



Octadecylsulfate ammonium salt was synthesised using the same procedure used to prepare hexylsulfate ammonium salt. Yield 80%. 1-Octyl-3-methylpyridinium bromide (12.95 g, 45.25 mmol) was dissolved in water (100 mL) and a solution of octadecyl sulfate ammonium salt (16.63 g, 45.25 mmol) in water (100 mL) was added. This solution was stirred for 10 min before being extracted with CH_2Cl_2 (3 x 100 mL). The combined extracts were washed with distilled water (3 x 100) until a negative AgNO_3 test was obtained. The organic layer was dried (anhydrous MgSO_4), filtered and evaporated to afford the target product. The ionic liquid was dried overnight at 60 °C under high vacuum. Yield 96%.





^1H NMR (DMSO- d_6) δ 9.03 (s, 1H), 8.94 (d, J = 5.9 Hz, 1H), 8.46 (d, J = 8.0 Hz, 1H), 8.06 (dd, J = 8.0, 5.9 Hz, 1H), 4.55 (t, J = 7.4 Hz, 2H), 3.68 (t, J = 6.6 Hz, 2H) 2.50 (s, 3H), 1.91 (quin, J = 7.4 Hz, 2H), 1.46 (quin, J = 6.6 Hz, 2H), 1.35-1.14 (br s, 40H), 0.85 (2 x t, 6H), ^{13}C NMR (DMSO- d_6) δ 145.7, 144.3, 142.0, 138.8, 127.4, 65.5, 60.6, 31.4, 31.2, 30.8, 29.2, 29.2, 29.1, 29.0, 28.8, 28.6, 28.5, 25.6, 25.5, 22.2, 22.1, 17.8, 13.8 13.7. HRMS +ve calcd 206.1903 found 206.1909 –ve calcd 349.2418 found 349.2435.

NMR Spectra



3-(Hexyloxycarbonyl)-1-methylpyridinium bis(trifluoromethylsulfonyl)amide:





1-Methyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:





3-(Butoxycarbonyl)-1-butyropyridinium bis(trifluoromethylsulfonyl)amide:



1-Hexyl-3-(hexyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:




1-Octyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide:




1-Octyl-3-methylpyridinium hexylsulfate:



Dec07-2011
YS-1-116 C6Sulfate IL



Sep06-2013
YS-1-116 C6Sulfate IL C




1-Octyl-3-methylpyridinium decylsulfate:




1-Octyl-3-methylpyridinium octadecylsulfate:

Jul30-2012
YS-2-C18 IL




Sep09-2013
YS-2-1 C18 IL C



HPLC Data

3-(Hexyloxycarbonyl)-1-methylpyridinium bis(trifluoromethylsulfonyl)amide




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	1.051	MM	0.1385	89.28242	10.74156	3.1614
2	4.691	MM	0.0595	2734.87866	766.50745	96.8386

Totals : 2824.16108 777.24901

1-Methyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	5.014	MM	0.0605	2446.08032	673.54529	99.4292
2	5.428	MM	0.0743	14.04152	3.15108	0.5708

Totals : 2460.12185 676.69637

3-(Butoxycarbonyl)-1-butylpyridinium bis(trifluoromethylsulfonyl)amide




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	4.666	MM	0.0572	1433.25354	417.60999	99.5425
2	4.959	MM	0.0585	6.58720	1.87700	0.4575

Totals : 1439.84074 419.48699

1-Hexyl-3-(hexyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	2.525	MM	0.0818	76.25480	15.54382	3.3861
2	4.669	MM	0.0424	34.28400	13.48918	1.5224
3	5.166	MM	0.0710	2141.45459	502.70697	95.0915

Totals : 2251.99339 531.73997

1-Octyl-3-(octyloxycarbonyl)pyridinium bis(trifluoromethylsulfonyl)amide




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	5.546	MM	0.0820	1746.98718	355.13049	97.2857
2	6.163	MM	0.0558	10.50129	2.80537	0.5848
3	6.516	MM	0.1201	38.23985	5.30825	2.1295

Totals : 1795.72832 363.24411

1-Methyl-3-octylpyridinium hexyl sulfate




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	1.510	MM	0.0595	4.90458	1.37443	0.5833
2	1.815	MM	0.1286	24.94847	3.23271	2.9672
3	4.863	MM	0.0562	810.96033	240.55383	96.4495

Totals : 840.81338 245.16098

1-Methyl-3-octylpyridinium decyl sulfate




Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	1.510	MM	0.1418	124.00526	11.35557	2.7157
2	1.774	MM	0.2238	89.67902	6.67872	1.9640
3	4.875	MM	0.0682	4352.54883	1063.32397	95.3203

Totals : 4566.23311 1081.35826

1-Methyl-3-octylpyridinium octadecyl sulfate



Signal 3: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	1.619	MM	0.0571	9.91619	2.89270	0.4773
2	4.878	MM	0.0733	2067.59888	470.38647	99.5227

Totals : 2077.51507 473.27918

References

1. J. R. Harjani, R. D. Singer, M. T. Garcia, P. J. Scammells, *Green Chem.* **2009**, *11*, 83-90.
2. J. R. Harjani, R. D. Singer, M. T. Garcia, P. J. Scammells, *Green Chem.* **2008**, *10*, 436-438.